Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 2/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.30 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | CLK3 | P49761 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18256662 | 0.80 | FDPS (0.54) | CYP17A1CYP1A2FDPS | |
| SCHEMBL17008880 | 0.73 | TGFBR1 (0.37) | FDPSPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17020121 | 0.73 | FDPS (0.37) | CYP17A1CYP1A2FDPS | |
| SCHEMBL3190866 | 0.72 | KDM4E (0.42) | CYP1A2ADORA2AADORA1 | |
| SCHEMBL17008881 | 0.70 | ALDH1A1 (0.38) | CYP17A1CYP1A2FDPS | |
| SCHEMBL17008902 | 0.69 | CSNK2A1 (0.42) | CYP17A1FDPSADORA2A | |
| SCHEMBL32683372 | 0.68 | CYP17A1 (0.38) | CYP17A1CYP1A2 | |
| SCHEMBL17008875 | 0.68 | MAPK14 (0.41) | PI4KAPI4KB | |
| SCHEMBL17008872 | 0.68 | MEN1 (0.50) | CYP1A2FDPSADORA2ADYRK1A | |
| SCHEMBL6123472 | 0.65 | CYP17A1 (0.42) | CYP17A1CYP1A2FDPSTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106170478-B | GPR142 agonist compound | 伊莱利利公司 | 2019-04-09 | — | — | CN | disclosed |
| EP-3105207-B1 | GPR142 AGONIST COMPOUNDS | LILLY CO ELI (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9861613-B2 | GPR142 agonist compounds | ELI LILLY AND COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| US-9861613-B2 | GPR142 agonist compounds | ELI LILLY AND COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170165234-A1 | GPR142 Agonist Compounds | ELI LILLY AND COMPANY | 2017-06-15 | — | — | US | disclosed |
| US-20170165234-A1 | GPR142 Agonist Compounds | ELI LILLY AND COMPANY | 2017-06-15 | — | — | US | disclosed |
| US-20170165234-A1 | GPR142 Agonist Compounds | ELI LILLY AND COMPANY | 2017-06-15 | — | — | US | disclosed |
| CN-106170478-A | GPR142 agonist compound | 伊莱利利公司 | 2016-11-30 | — | — | CN | disclosed |
| WO-2015120768-A1 | GPR142 AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165234-A1 | GPR142 Agonist Compounds | GPR3, GPR142, GPR27 | CYP17A1 1245/4885CYP1A2 1878/4885FDPS 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.